Brief: GlobeImmune Celgene Corporation entered into Celgene amendment' agreement
Aug 4 (Reuters) - GlobeImmune Inc GBIM.O : * Says on July 31, 2015 co and Celgene Corporation entered into Celgene amendment' agreement * Says Celgene amendment provides company's gi-6100 program replaced the company's gi-3000 program as a drug candidate * Globeimmune -co eligible for milestone payments of up to $145 mln,and tiered royalty payments in the low teens for sales of gi-6100 * Source text for Eikon ID:nEOL9G7tff * Further company coverage GBIM.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on GlobeImmune
See all newsBrief: GlobeImmune announces updates
Brief: Globeimmune to delist and deregister common stock from Nasdaq Capital Market
Brief: GlobeImmune reports Q1 loss per share of $0.15
Brief: GlobeImmune hires Cantor Fitzgerald to assist in review of strategic alternatives
Brief: GlobeImmune says net income of $0.9 million for three months ended September 30, 2015